AMRI’s Rensselaer labs and manufacturing facilities receive SafeBridge Potent Compound Safety Certification

SAFEBRIDGE^® CONSULTANTS, INC. (“SafeBridge”), headquartered in Mountain View, California, has announced that AMRI’s high potency research laboratories and GMP-manufacturing facilities in Rensselaer, New York have met the criteria established under the SafeBridge program for “Potent Compound Safety Certification” and have been deemed competent and proficient in the safe handling of potent active pharmaceutical ingredients (“APIs”). The SafeBridge Potent Compound Safety Certification applies to specific AMRI laboratories and manufacturing areas designed for the research, development and manufacture of potent compounds.

SafeBridge conducted a 60-element review of AMRI programs, procedures and facilities used for the containment and control of potent APIs. Based on the quantitative results of the Potent Compound Safety Certification program, SafeBridge certifies that AMRI meets current industry standards for the safe handling of potent APIs in the identified areas.

SAFEBRIDGE CONSULTANTS, INC.